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Advances in directed immunotherapeutic 
approaches to cancer have led to the development 
of monoclonal antibodies that target the immune 
checkpoint T-cell receptor or ligand, programmed 
death-1 (PD1) or PDL1. With the emergence of 
immune checkpoint inhibitors, there have been 
several reports of cutaneous adverse reactions 
associated with them [1]. Lichenoid reactions  
secondary to PD1 inhibitors are well documented [1-
4]. However, inverse lichenoid eruption in the groin 
is a distinct variant that, to our knowledge, has only 
been reported once [2]. Herein, we describe two 
additional cases and propose that PD1 inhibitor 
induced inverse lichenoid eruption (PILE) be 
recognized as a new entity within the spectrum of 





An 82-year-old woman with Stage IVB lung 
adenocarcinoma treated with pembrolizumab every 
three weeks for 5 months was admitted for 
worsening perineal and intergluteal rash of 6 weeks’ 
duration. It started as a focal crusted plaque with 
pruritus, which was initially treated with zinc oxide 
barrier paste. The patient was switched to nystatin 
cream and oral fluconazole for 20 days by her 
oncologist owing to worsening erythema, pruritus, 
and significant pain. The antifungals led to no 
improvement. She denied a prior history of 
inflammatory skin disease. Physical examination 
showed deeply erythematous, malodorous, eroded 
plaques with overlying yellow-brown exudative 
crust in the inguinal folds, labia majora, perineum, 
and intergluteal folds (Figure 1A).  
Skin swabs for fungal and bacterial culture, as well as 
herpes simplex virus (HSV) 1 and 2 viral polymerase 
chain reaction were negative. Punch biopsy from the 
buttock showed superficial perivascular infiltrate of 
Abstract 
The increased use of monoclonal antibodies that 
target the immune checkpoint T cell receptor 
programmed death-1 (PD1) to treat numerous solid 
tumors has led to several reports describing 
associated cutaneous adverse events. Although 
lichenoid reactions have been well described, we 
propose that PD1 inhibitor-induced inverse lichenoid 
eruption (PILE) is a distinct variant. We describe two 
patients who presented with nearly identical deeply 
erythematous, malodorous, eroded anogenital 
plaques with focal crusting. Diagnosis of PILE was 
established given the biopsy findings and temporal 
association with PD1 inhibitor therapy. Treatment 
with clobetasol ointment was successful without 
necessitating discontinuation of immunotherapy. 
The findings were consistent with the only other 
previously published case of inverse lichenoid 
eruption in the groin secondary to PD1 inhibitors. 
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lymphocytes with foci of vacuolar alteration and 
individual necrotic keratinocytes (Figure 2). Twice 
daily treatment with clobetasol 0.05% ointment led 
to significant improvement within two weeks. At the 
time of admission, the patient and her daughters 
elected to pause the pembrolizumab therapy after a 
detailed discussion with the oncologist. 
Pembrolizumab therapy was reintroduced two 
months later, followed by recurrence of the rash, 
pain, and pruritus within days. Given the biopsy 
findings and temporal association with 
pembrolizumab, a diagnosis of PILE was established. 
The patient was encouraged to continue 
pembrolizumab since her symptoms were not life 
threatening and amenable to topical corticosteroids. 
Prophylactic application of clobetasol around the 
time of her infusions prevented future flares. 
Patient 2 
A 61-year-old woman with stage IIB lung 
adenocarcinoma treated with lobectomy and four 
cycles of adjuvant carboplatin/paclitaxel in 2011 had 
recurrence of her cancer in 2015. She was started on 
nivolumab in 2016 and switched to atezolizumab 
(PDL1 inhibitor) in 2017 owing to worsening disease. 
She developed a painful perineal and intergluteal 
rash about 30 months after the initiation of 
nivolumab, while on atezolizumab. The patient 
denied oral lesions and a prior history of 
inflammatory skin disease. Physical examination 
showed erythematous, malodorous, eroded plaques 
with focal crusting in the lower abdominal as well as 
inguinal folds, labia majora, mons pubis, perineum, 
and intergluteal folds (Figure 1B).  
Skin swab for HSV and serum desmoglein 1 and 3 
antibodies were negative. Punch biopsy from the left 
inguinal fold showed a dense lichenoid infiltrate in 
the superficial papillary dermis with lymphocytes, 
plasma cells, and neutrophils (figure not included 
because of acute necrosis and sloughing off of the 
epidermis, secondary to acute interface dermatitis 
from both biopsy specimens taken from the patient). 
Immunostaining for cytomegalovirus and HSV 1 and 
2 were negative. The nearly identical 
clinicopathologic findings as Patient 1 led to the 
diagnosis of PILE. The patient was successfully 
treated with twice daily application of clobetasol 
0.05% ointment. Atezolizumab was not discontinued 
secondary to the cutaneous eruption. Table 1 
summarizes both these cases along with the 
previously published case by Guggina et al. [2]. 
 
Case Discussion 
Cutaneous eruptions are commonly reported with 
PD1 inhibitors, occurring in close to one-third of 
patients [2]. Generalized dermatitis, pruritis, vitiligo, 
and lichenoid eruptions are among the most 
frequently described [1-6]. There is evidence that 
cutaneous adverse effects during anti-PD1 




Figure 1. A) Patient 1 shows deeply erythematous, eroded 
plaques with overlying yellow-brown exudative crust in the 
inguinal folds and labia majora. B) Patient 2 shows erythematous 
eroded plaques with focal crusting in the gluteal cleft. 
A 
B 
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Lichenoid reactions while on PD1 and PDL1 inhibitor 
immunotherapy present as discrete, erythematous, 
scaly papules or plaques on the trunk and 
extremities. Mucous membranes are usually spared 
[3]. Histopathologically, they show a greater 
lymphohistiocytic lichenoid infiltration, increased 
spongiosis, and increased epidermal necrosis when 
compared to non-drug related cases of lichen planus 
[1]. Although diffuse lichenoid and inverse 
psoriasiform eruptions have been reported with PD1 
inhibitors, the intertriginous presentations described 
in this case series are unique. There has only been 
one other report of a similar presentation, which was 
associated with nivolumab treatment for metastatic 
renal cell carcinoma [2]. We would therefore like to 
classify this PD1 inhibitor induced inverse lichenoid 
eruption (PILE) as a distinct entity. Based on our 
cases, it may manifest anywhere from 5 months to 
more than two years after initiation of 
immunotherapy. The pathogenesis of PILE is 
hypothesized to result from a localized T cell immune 
response [2]. A similarly distributed intertriginous 
eruption referred to as symmetrical drug-related 
intertriginous and flexural exanthema (SDRIFE) is  
postulated to be a type IV hypersensitivity involving 
CD4+ helper T cells. A type IV hypersensitivity might 
also explain why PILE does not occur after the first 
exposure without prior sensitization. The flexural 
predilection of both PILE and SDRIFE might result 
from occlusion, sweating, or the excretion of certain 
medications or their metabolites from eccrine glands 
[8]. Additionally, although this clinical presentation 
can be seen as part of toxic erythema of 
chemotherapy, neither of the patients received any 
chemotherapy. It should be noted that all patients 
identified with PILE thus far were female. However, 
the limited number of cases makes it is hard to 
postulate whether this occurred by chance or 
represents a true gender predisposition. 
High potency topical corticosteroids successfully 
treated both our patients. The only other report of a 
patient with PILE similarly noted complete resolution 
with clobetasol use and no recurrence despite 
continuation of nivolumab [2]. Thus, interruption of 
the PD1 inhibitor is not necessary. Prophylactic use 
of topical corticosteroid around the time of infusions 
is another option to prevent flares. 
Figure 2. A) Punch specimen histopathology from Patient 1 showing superficial perivascular infiltrate of lymphocytes with foci of 
vacuolar alteration. H&E, 100×. B) Punch specimen from Patient 1 higher-power view (H&E, 400×) showing individual necrotic 
keratinocytes. 
A B 
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Conclusion 
With the increasing use of PD1 and PDL1 inhibitors, 
dermatologists should be cognizant of the variable 
presentations of cutaneous adverse events and their 
management so as to ensure proper diagnosis, 
optimal treatment, and better health-related quality 
of life for their patients. Further investigation is  
required to better understand the pathogenesis of 
this distinct variant.  
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Table 1. Characteristics of the three cases and therapeutic response. 
Case No./ 









Eruption Pathology Findings  Treatment  






infiltrate of lymphocytes 
with foci of vacuolar 
alteration and individual 
necrotic keratinocytes 
Clobetasol 





Stage IIB lung 






Base of a subepidermal 
blister with dense 




cells and neutrophils 
Clobetasol 
ointment  
3/F/76 [2] Nivolumab  
Metastatic renal 




Lichenoid infiltrate in the 





infiltrate with scattered 
eosinophils and necrotic 
keratinocytes 
Clobetasol 
ointment  
